Write your message
Volume 4, Issue 4 (Fall 2019)                   J Obstet Gynecol Cancer Res 2019, 4(4): 131-134 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Haghighat S. New Treatment of Advanced Ovarian Cancer: A Literature Review. J Obstet Gynecol Cancer Res. 2019; 4 (4) :131-134
URL: http://jogcr.com/article-1-237-en.html
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran , sh.haghighat2010@yahoo.com
Abstract:   (1397 Views)

Epithelial ovarian cancer is one of the most common gynecological malignancies worldwide with an incidence of 225000 cases annually. For most patients, multimodality treatment including cytoreductive surgery and combination chemotherapy is an accepted standard of care. Despite the relatively favorable response to initial treatment, relapse free survival and overall survival are disappointing in patients with advanced ovarian cancer. Therefore, new treatment approaches have been proposed in recent years. The present review aims to describe the most relevant data published during the last four years on new approach to advanced ovarian cancer. Therefore, relevant studies were searched through Pubmed, Cochrane library and Scopus database published online until 2019. The most important changes studied in recent years have included the addition of new chemotherapy or targeted agent to first-line chemotherapy. Although combination of intravenous paclitaxel and carboplatin is currently accepted as the standard of care for treatment of advanced ovarian cancer, discussion around the intraperitoneal chemotherapy is still an important challenge. Additionally, much efforts have been dedicated to design an appropriate maintenance treatment as a goal of diminish the risk of recurrence. This review summarizes the results of most recent phase 3 trials surrounding optimal first-line chemotherapy, addition of a targeted agent including bevacizumab and maintenance treatment.

Full-Text [PDF 129 kb]   (1254 Downloads) |   |   Full-Text (HTML)  (357 Views)  
Systematic Review: Review | Subject: Gynecology Oncology
Received: 2019/10/13 | Accepted: 2019/11/28 | Published: 2020/01/5

1. Marchetti C, Muzii L, Romito A, Panici PB. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095-1103. [DOI:10.2147/OTT.S155425] [PMID] [PMCID]
2. Colombo N, Sessa C, Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology. 2019;30:672-705. [DOI:10.1093/annonc/mdz062] [PMID]
3. National Comprehensive Cancer Network Epithelial ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, 2019 ver1. 2019. [Accessed March 8, 2019. Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
4. Lopez J, Banerjee S, Kaya SB. New development in the treatment of ovarian cancer_ future prospective. Annals of Oncology. 2013;24:69-76. [DOI:10.1093/annonc/mdt475] [PMID] [PMCID]
5. Zhang G, Zhu Y, Liu C, Chao G, Cul R and Zhang Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019;12:33. [DOI:10.1186/s13048-019-0509-1] [PMID] [PMCID]
6. Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian cancer immunotherapy: Turning up the heat. Int J Mol Sci. 2019;20:E2927. [DOI:10.3390/ijms20122927] [PMID] [PMCID]
7. Xinjie Du, Xiaojie Lin. Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer. JBUON 2019; 24(5): 2035-2040.
8. Gill SE, Mc Gree ME, Weaver AL, Cliby WA, Langstraat CA. optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gyenecol Oncol. 2017;144:266-273. [DOI:10.1016/j.ygyno.2016.11.021] [PMID]
9. Loizzi V, Leone L, Camporeale A, Resta L, Selaggi L, Cicinelli E, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: A single-institution experience and review of the literature. Oncology. 2016;91:211-216. [DOI:10.1159/000447743] [PMID]
10. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953 [DOI:10.1056/NEJMoa0908806] [PMID]
11. . Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer (Review). www.cochrane library.com. 2010. Issue8.
12. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24:24-32. [DOI:10.1093/annonc/mdt333] [PMID]
13. Katsumata N. Dose-dense approaches to ovarian cancer treatment. Cur Treat Options Oncol. 2015;16:21. [DOI:10.1007/s11864-015-0338-4] [PMID]
14. Marchetti C, De Felice F, Musella A, Palaia I, Monti M, Musio D, et al. weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis. Oncotarget. 2016;7:58709-58715. [DOI:10.18632/oncotarget.11094] [PMID] [PMCID]
15. Marchetti C, De Felice F, Di Pinto A, D'Oria O, Aleksa N, Musella A, et al. Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2018;125:30-34. [DOI:10.1016/j.critrevonc.2018.02.016] [PMID]
16. Clamp AR, McNeish L, Dean A, Gallardo D, Weon-Kim J, O'Donnell D, et al. ICON8: A GCIG phase III randomized trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression free survival (PFS) analysis. Annals of Oncology. 2017;28:627. [DOI:10.1093/annonc/mdx440.039]
17. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Feriedlander M, et al. Evaluation of new treatment platinium-based regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup. Journal of Clinical Oncology. 2009;27;1419-1425. [DOI:10.1200/JCO.2008.19.1684] [PMID] [PMCID]
18. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Sys Rev. 2011. [DOI:10.1002/14651858.CD005340.pub3] [PMCID]
19. Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Asco.org/edbook. 2016;143-151. [DOI:10.14694/EDBK_158927] [PMID]
20. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. AM.Cancer. 2007;109:692-702. [DOI:10.1002/cncr.22466] [PMID]
21. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clinical Oncology. 2019;37:2317-2328. [DOI:10.1200/JCO.19.01009] [PMID]
22. Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: A meta-analysis. Cancer. 2010;116:5251-5260. [DOI:10.1002/cncr.25487] [PMID] [PMCID]
23. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-5. [DOI:10.1200/JCO.2003.07.013] [PMID]
24. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374-82. [DOI:10.1200/JCO.2014.55.7348] [PMID]
25. Xu X, Yin S, Guo H, Li M, Qian Z, Tian X, et al. Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis. Cancer Management and Research. 2019;11:4119-4128. [DOI:10.2147/CMAR.S187119] [PMID] [PMCID]
26. Vergote I, Du Bois A, Floguet A, Rau J, Kim JW, Del Campo JM, et al. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019. [DOI:10.1016/j.ygyno.2019.08.024] [PMID]
27. Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017;9;253-267. [DOI:10.1177/1758834016687254] [PMID] [PMCID]
28. Ledermann JA. PARP inhibitors in ovarian cancer. Annals of Oncology. 2016;27:40-44. [DOI:10.1093/annonc/mdw094] [PMID]
29. Melissa k, Fray, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecologic Oncologic Research and Practice. .2017;4:4. [DOI:10.1186/s40661-017-0039-8] [PMID] [PMCID]
30. Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Design, Development and Therapy. 2018;12:605-617. [DOI:10.2147/DDDT.S130809] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.